Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; patients must also have a CD count >  cells/mm^ with an undetectable viral load
Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests
Human immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, however HIV-positive patients must meet the following criteria:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
Human immunodeficiency virus (HIV) positive with CD count < () cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >= () cells/microliter, and no known detectable viral load, at the time of study entry; note also that HIV testing is not required for eligibility for this protocol
Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective\r\n* They must have an undetectable viral load\r\n* They must have a CD count of greater than  cells/mcL \r\n* They must not be receiving prophylactic therapy for an opportunistic infection
Patients who are human immunodeficiency virus (HIV)-positive are eligible if: \r\n* CD+ cell count greater or equal to  cells/mm^\r\n* If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; for experimental cancer therapeutics with CYPA/ interactions, protease inhibitor therapy is disallowed; suggested regimens to replace protease inhibitor therapy include dolutegravir given with tenofovir/emtricitabine; raltegravir given with tenofovir and emtricitabine; once daily combinations that use pharmacologic boosters may not be used\r\n* No history of non-malignancy acquired immune deficiency syndrome (AIDS)-defining conditions other than historical low CD+ cell counts\r\n* Probable long-term survival with HIV if cancer were not present
Patients with known human immunodeficiency virus (HIV) may be eligible providing they meet the following additional criteria:\r\n* Cluster of differentiation (CD) cells >= /uL\r\n* Serum HIV viral load of < , IU/ml\r\n* No current antiretroviral therapy\r\n** Tests must be obtained within  days prior to registration; patients who are HIV positive (+) and do not meet all of these criteria are not eligible for this study (HIV/hepatitis testing are not required for patients without known infection)
Patients positive for human immunodeficiency virus (HIV) are eligible only if they meet all of the following:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD count above  cells/mcL, and an undetectable HIV viral load on standard PCR-based tests
Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A cluster of differentiation (CD) count above  cells/mcL and an undetectable HIV viral load on standard PCR-based tests
Patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:\r\n* No history of acquired immune deficiency syndrome (AIDS)-related complications other than a history of low CD+ T-cell count (< /mm^) prior to initiation of combination antiretroviral therapy; on study CD+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low\r\n* Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia\r\n* Patient must have serum HIV viral load of <  copies/mm^\r\n* Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy\r\n* Patient must not be receiving protease inhibitors or once daily formulations containing cobicistat, stavudine, or on regimens containing stavudine or zidovudine\r\n* It is recommended to utilize a regimen of the integrase inhibitor, dolutegravir, combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine
Patients with hepatitis B virus infection must have undetectable hepatitis B virus (HBV) on suppressive therapy and no evidence of HBV-related hepatic damage; patients with hepatitis C virus infection are eligible if complete eradication therapy has been successfully completed, and there is no detectable hepatitis C virus (HVC) or related hepatic damage; patients with known human immunodeficiency virus (HIV) infection are eligible if they meet all of the following criteria:\r\n* Patient must have no history of acquired immune deficiency syndrome (AIDS)-related complications, other than a history of low CD+ T-cell count (< /mm) prior to initiation of combination antiretroviral therapy; on study CD+ T-cell count may not be informative due to leukemia and should not be used as an exclusion criterion if low\r\n* Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the leukemia\r\n* Patient must have serum HIV viral load of <  copies/mm^\r\n* Patient must be on combination antiretroviral therapy with minimal pharmacokinetic interactions with study therapy and minimal overlapping clinical toxicity with protocol therapy; (recommend a regimen of the integrase inhibitor dolutegravir combined with either disoproxil fumarate/emtricitabine or dolutegravir combined with tenofovir alafenamide/emtricitabine)\r\n* Protease inhibitors and once daily formulations containing cobicistat are NOT allowed\r\n* Stavudine and zidovudine (AZT) are NOT allowed
Human immunodeficiency virus (HIV) positive with cluster of differentiation  (CD) count <  cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter within  days prior to step  registration; note also that HIV testing is not required for eligibility for this protocol
Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART); and\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections; and\r\n* A CD count above  cells/uL and an undetectable HIV viral load on standard PCR-based tests
Human immunodeficiency virus (HIV) positive patients are not excluded, but to enroll, must meet all of the below criteria:\r\n* HIV is sensitive to antiretroviral therapy\r\n* Must be willing to take effective antiretroviral therapy that has minimal overlapping toxicity and pharmacokinetic interactions with protocol therapy\r\n* No history of HIV-related opportunistic disease or acquired immune deficiency syndrome (AIDS)-defining conditions within past  months other than historic CD+ T-cell counts below  cells/mm^\r\n* Expected long-term survival if lymphoma were not present
Patients with human immunodeficiency virus (HIV) infection are eligible, provided they meet the following:\r\n* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness\r\n* Cluster of differentiation (CD)+ cells nadirs > /mm^ within  days prior to registration\r\n* Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load <  copies/mm^ within  days prior to registration\r\n* Note: HIV+ patients who enroll on this study and are assigned to treatment with ixazomib may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P A
Known human immunodeficiency virus (HIV) positive with CD count <  cells/microliter. Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter within  days prior to registration; note also that HIV testing is not required for eligibility for this protocol; this exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within  days prior to registration: stable and adequate CD counts (>=  mm^), and serum HIV viral load of < , IU/ml; patients must be on a stable anti-viral therapy
Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD) count <  cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter within  days prior to registration; note also that HIV testing is not required for eligibility for this protocol
HIV patients under treatment with highly active antiretroviral therapy (HAART) within  days prior to registration regardless of CD count; (Note: HIV testing is not required for eligibility for this protocol as it is self-reported; this exclusion criterion is necessary because the treatments involved in this protocol may be immunosuppressive and/or interact with HAART)
Patients positive for human immunodeficiency virus (HIV) are eligible only if they have all of the following:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard PCR-based tests
Severe, active co-morbidity defined as follows: \r\n* Human immunodeficiency virus (HIV) positive with CD count <  cells/microliter; Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter within  days prior to registration; Note also that HIV testing is not required for eligibility for this protocol\r\n* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol; (patients on Coumadin or other blood thinning agents are eligible for this study)
No history of the following:\r\n* Autoimmunity requiring systemic immunosuppression within  years\r\n* Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following:\r\n** CD counts >=  mm^\r\n** Serum HIV viral load of < , IU/ml
Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patient cannot have poorly controlled human immunodeficiency virus (HIV), or CD < ; HIV positive patients are allowed on this study if they have a CD count >= , and are on a stable antiviral regimen
Patients who have previously tested positive for human immunodeficiency virus (HIV) are NOT excluded from this study (please note: testing of all patients wishing to enroll is NOT required), but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard PCR-based tests
Patients with human immunodeficiency virus (HIV) infection may be eligible provided they meet the following:\r\n* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness\r\n* Cluster of differentiation (CD)+ cells nadirs > /mm^\r\n* Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load <  copies/mm^; please note: HIV+ patients who enroll on this study may need to modify their anti-retroviral therapy prior to receiving protocol therapy if they are on strong inducers or potent inhibitors of cytochrome P A; adverse events in HIV+ patients will be reported separately
Positive test for the human immunodeficiency virus (HIV) unless undetectable viral load within  months of enrollment (HIV ribonucleic acid [RNA] less than  copies/mL) and on highly active antiretroviral therapy (HAART) therapy
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; it is not necessary to conduct HIV testing at screening; patients who are HIV-positive with undetectable viral loads, not on interacting antiretroviral therapy, and have CD counts above /mm^ may be eligible after discussion with the principal investigator
Patients who are known to be human immunodeficiency virus (HIV)-positive at registration are eligible at the time of registration as long as:\r\n* CD+ cell count >=  cells/mm^\r\n* If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the study drugs; once daily combinations that use pharmacologic boosters may not be used\r\n* No history of non-malignancy acquired immune deficiency syndrome (AIDS)-defining conditions other than historical low CD+ cell counts
Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests
Human immunodeficiency virus (HIV) positive subjects with  or more of the following:\r\n* Not receiving highly active antiretroviral therapy\r\n* A change in antiretroviral therapy within  months of the start of screening (except if, after consultation with the sponsor on exclusion criterion below; a change is made to avoid a potential drug-drug interaction with the study drug)\r\n* Receiving antiretroviral therapy that may interfere with the study drug (consult the sponsor for review of medication prior to enrollment)\r\n* CD count <  at screening\r\n* An acquired immunodeficiency syndrome-defining opportunistic infection within  months of the start of screening
Human immunodeficiency virus (HIV)-positive patients are eligible provided the following criteria are met: CD count > /mm^, an undetectable viral load, and not receiving prophylaxis antibiotics
Patients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a cluster of differentiation (CD) count >=  cells/microliter within  days prior to registration as documented in the medical record; HIV testing is not required for eligibility for this protocol
Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYPA (e.g. regimens containing ritonavir, cobicistat, efavirenz or etravirine) are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYPA are ineligible; patients with poorly controlled HIV are not eligible
Human immunodeficiency virus (HIV)+ patients are eligible for the trial provided they meet the other study criteria in addition to the following:\r\n* CD+ T-cells >= /mm^\r\n* HIV sensitive to antiretroviral therapy\r\n* Zidovudine not allowed\r\n* Long term survival anticipated on the basis of HIV alone were it not for the lymphoma\r\n* No concurrent acquired immunodeficiency syndrome (AIDS)-defining illness other than the lymphoma
Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective\r\n* They must have a CD count of greater than  cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; HIV-positive patients who are not on highly active anti-retroviral therapy (HAART) and have CD counts >  will be considered on an individual basis
Patients serologically positive for human immunodeficiency virus (HIV), hepatitis (Hep) B, Hep C are eligible as long as the viral loads are undetectable by quantitative polymerase chain reaction (PCR); HIV positive patients must have CD count >=  cells per cubic millimeter at enrollment, be on stable antiretroviral therapy and have no reported opportunistic infections within  months prior to enrollment
Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within  days prior to registration: stable and adequate CD counts (>=  mm^), and serum HIV viral load of < , IU/ml; patients may be on or off anti-viral therapy so long as they meet the CD count criteria
Human Immunodeficiency virus (HIV) positive patients are included if CD+ T-cell count >  cells/uL; on stable antiretroviral therapy for >  year with HIV viral load <  copies/mL, and no history of opportunistic infections in >  year
Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard PCR-based tests
Human immunodeficiency virus (HIV) positive with detectable viral load, or anyone not on stable anti?viral (highly active antiretroviral therapy [HAART]) regimen
In order for patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) to be eligible, they must be on a stable highly active antiretroviral therapy (HAART) regimen, have CD counts > , with no detectable viral load on quantitative polymerase chain reaction (PCR)
Human immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART) that does not include strong inhibitors and strong or moderate inducers of CYPA\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
Human immunodeficiency virus (HIV)-positive patients are eligible provided they meet all the other protocol eligibility criteria including the following:\r\n* Undetectable HIV viral load by standard clinical assay\r\n* Willing to adhere to antiretroviral therapy that has minimal overlapping toxicity or pharmacokinetic interactions with protocol therapy\r\n* CD+ T cell counts of /mm^ or greater\r\n* No acquired immunodeficiency syndrome (AIDS)-defining events other within the past  months\r\n* Near normal life expectancy if not for the presence of the cancer\r\nAlso, HIV-positive patients must not be on HIV medications considered to be inhibitors or inducers of CYPA
Human immunodeficiency virus (HIV) positive patients who are otherwise eligible for this study may be enrolled if they meet the following requirements:\r\n* Are seen in the infectious disease (ID)/HIV clinic prior to enrollment on study for the purpose of determining eligibility and for local coordination of HIV care during the peri-transplant period\r\n** Are on maximally active anti-HIV regimen to control disease as determined appropriate by the ID/HIV physicians; for the majority of patients, this will be a highly active anti-retroviral therapy (HAART)-type therapy including a protease inhibitor\r\n* CD+ >= /uL\r\n* HIV ribonucleic acid (RNA) viral load =< , copies per mL on each of samples  weeks apart; the most recent level must be within  days of enrollment
Known human immunodeficiency virus (HIV)-positive unless on highly active antiretroviral therapy (HAART), and/or known Hepatitis B or C on treatment. Drug interactions between those agents and these experimental agents are wholly unknown (screening not required).
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy may be eligible if there are no pharmacokinetic interactions with the agents used on the study, stable on chimeric antigen receptor T cell (CART) therapy and cluster of differentiation (CD) is >  and viral load is undetectable
Known human immunodeficiency virus (HIV)-positive and on highly active antiretroviral therapy (HAART), and/or hepatitis B or C on treatment
Highly active antiretroviral therapy (HAART) for HIV+ patients:\r\n* All HIV+ patients must be willing to be compliant with HAART\r\n* Group I  on HAART for  month with stable disease; however, no minimum time restriction for patients with progressive and/or end-organ threatening disease\r\n* Group II  no minimum time restriction on prior HAART, patients may be HAART naive
Patients with human immunodeficiency virus (HIV) who are not receiving cytochrome p inhibitors, and who have a minimum of + CD+ cells/mm^, an undetectable viral load, and no history of acquired immunodeficiency syndrome (AIDS) indicator conditions
Patient must be willing to undergo testing for human immunodeficiency virus (HIV) if not tested within the past  months. If HIV+ positive, patient will be eligible if: his/ her CD+ count ? /?L; his/her viral load is undetectable; he/she is currently receiving highly active antiretroviral therapy (HAART).
Human immunodeficiency virus (HIV) infection, unless receiving effective antiretroviral therapy with undetectable viral load and normal CD counts
PHASE I STUDY ELIGIBILITY CRITERIA:\r\nHuman immunodeficiency virus (HIV)-positive patients on antiretroviral therapy are ineligible; however, patients with long-standing (>  years) HIV on antiretroviral therapy >  month (undetectable HIV viral load and CD count >  cells/uL) may be eligible if the PI determines no anticipated clinically significant drug-drug interactions
PHASE II STUDY COHORT  TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHIV-positive patients on anti-retroviral therapy are ineligible; however, patients with long-standing (>  years) HIV on antiretroviral therapy >  month (undetectable HIV viral load and CD count >  cells/uL) may be eligible if the PI determines no anticipated clinically significant drug-drug interactions
PHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT  ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nHIV-positive patients on combination antiretroviral therapy are ineligible; however, patients with long-standing (>  years) HIV on antiretroviral therapy >  month (undetectable HIV viral load and CD count >  cells/uL) may be eligible if the PI determines no anticipated clinically significant drug-drug interactions
PHASE II COLORECTAL CANCER COHORT  (MEDI+C ONLY):\r\nHIV-positive patients on anti-retroviral therapy are ineligible; however, patients with long-standing (>  years) HIV on antiretroviral therapy >  month (undetectable HIV viral load and CD count >  cells/?L) may be eligible if the PI determines no anticipated clinically significant drug-drug interactions
Patients with a detectable human immunodeficiency virus (HIV) viral load or who are HIV-positive AND have a resistant genotype
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible provided that they meet the following criteria in addition to the other protocol criteria: \r\n* Cancer as the only acquired immunodeficiency syndrome (AIDS)-defining condition\r\n* Cluster of differentiation (CD) cell count >= \r\n* Treatment sensitive HIV and prospects for long term survival on the basis of HIV disease alone\r\n* Willing to take anti-HIV therapy that will have minimal potential for pharmacokinetic interactions with GDC-
Human immunodeficiency virus (HIV) positive patients are allowed on this study if they have a CD count > , and are on a stable antiviral regimen; patients with poorly controlled HIV or other chronic active viral infections will be excluded
RANDOMIZED PHASE II (ARMS K AND L): HIV positive patients are eligible provided they meet the other protocol criteria including the following:\r\n* Long term survival expected were it not for the cHL\r\n* HIV viral loads undetectable by standard clinical HIV testing\r\n* Willing to adhere to effective combination antiretroviral therapy
For patients with HIV-associated KS:\r\n* Must be receiving, and adherent to, a highly active antiretroviral therapy (HAART) regimen consistent with current clinical guidelines\r\n* Must have been receiving HAART for at least one month\r\n* Must have achieved an HIV viral load (VL) < , copies/mL
Human immunodeficiency virus (HIV) positive (+) patients with CD counts >=  cells/mm^ on anti-viral therapy are eligible for the study
Patients with known active human immunodeficiency virus (HIV) infection; patients with chronic HIV with a CD > , undetectable viral load by PCR, without opportunistic infection, and on a stable regimen of highly active anti-retroviral therapy (HAART) therapy would be eligible
Patients receiving antiretroviral therapy (highly active antiretroviral therapy [HAART]) for human immunodeficiency virus (HIV) infection are excluded from the study
Human immunodeficiency virus (HIV) infection, unless the patient is receiving effective antiretroviral therapy with undetectable viral load and normal CD counts
Patients known to be human immunodeficiency virus (HIV) positive must be stable and currently receiving antiretroviral therapy with a CD count > 
Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active antiretroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR) -based tests
Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within  weeks prior to randomization:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART) and;\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections; and\r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard PCR-based tests
REGISTRATION TO TREATMENT (STEP ): Patients who are human immunodeficiency virus (HIV) positive are eligible if they have undetectable HIV viral load and CD+ T-cell count >= /mm^
REGISTRATION TO TREATMENT (STEP ): Patients who are human immunodeficiency virus (HIV) positive are eligible if they have undetectable HIV viral load and CD+ T-cell count >= /mm^
Patient with human immunodeficiency virus (HIV) who require anti-viral or supportive care that interacts with the study drugs are not eligible
For human immunodeficiency virus (HIV)+ patients: documented HIV- infection with CD count >  cells/mm^ and viral load <  copies/mL, within  days of day .
Human immunodeficiency virus (HIV)-positive patients on highly active antiretroviral therapy (HAART) are excluded
HIV positive with CD count <  cells/microliter; note that patients who are human immunodeficiency virus (HIV) positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter prior to registration; note also that HIV testing is not required for eligibility for this protocol
Human immunodeficiency virus (HIV)-positive subjects positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive subjects must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) \r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* CD count above  cells/mcL and an undetectable HIV viral load on standard PCR-based test
Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard PCR-based tests
Patients positive for human immunodeficiency virus (HIV) are not excluded from this study, but HIV-positive patients must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) that does not include strong or moderate CYPA inducers or inhibitors\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections \r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based test
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; HIV-positive patients not on antiviral therapy with undetectable viral loads and CD counts > , and after confirmation of eligibility after discussing with the study chair are eligible
Patients with a known history of human immunodeficiency virus (HIV) are eligible, if they meet all of the following conditions:\r\n* No history of HIV complications with the exception of cluster of differentiation (CD) count <  cells/mm^\r\n* No antiretroviral therapy with overlapping toxicity such as myelosuppression\r\n* HIV viral loads below the limit of detection\r\n* No history of highly active antiretroviral therapy (HAART)-resistant HIV
Healthy human immunodeficiency virus (HIV)-infected patients are eligible, provided that they meet all the other study criteria in addition to the following (HIV testing is not required for study enrollment):\r\n* CD+ cell count >= /mm^\r\n* HIV viral loads undetectable by standard clinical tests
Patients who are human immunodeficiency virus (HIV) positive may participate if they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective\r\n* They must have a cluster of differentiation (CD) count of greater than  cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection
Patients with human immunodeficiency virus (HIV) infection are not automatically excluded, but must meet the following criteria: cluster of differentiation (CD) count is > /cu mm and their viral load is <  copies/ml; use of highly active anti-retroviral therapy (HAART) is allowed
Patients with concurrent human immunodeficiency virus (HIV) infection may be enrolled if compliant with  or more drug anti-retroviral regimen and virus load less than  copies/ml and CD count greater than  cells/ml, and no concurrent opportunistic infection or other malignancy
Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection who are taking chronic anti-retroviral therapy (HAART) are ineligible if there is a potential for drug-drug interactions with the chemotherapeutic agents; patients with a known confirmed diagnosis of HIV infection who meet standard eligibility criteria and are not taking HAART with a potential for drug-drug interactions are eligible
Human immunodeficiency virus (HIV)-positive patients will be excluded unless antiretroviral therapy can be safely withheld during chemotherapy administration, based on clinical determination of infectious disease team evaluation
Patients with HIV disease are eligible for this study provided that:\r\n* Patients will be seen in the infectious disease (ID)/HIV clinic prior to enrollment on study for the purpose of determining eligibility and for local coordination of HIV care during the peri-transplant period\r\n* Must be on a maximally active anti-HIV regimen to control disease as determined appropriate by the ID/HIV physicians; for the majority of patients, this will be a highly active anti-retroviral therapy (HAART)-type therapy including a protease inhibitor\r\n* Cluster of differentiation (CD)+ >= /uL\r\n* HIV ribonucleic acid (RNA) viral load =< , copies per mL on each of samples  weeks apart; the most recent level must be within one month of enrollment
Patients known to be human immunodeficiency virus (HIV) positive are eligible if they meet the following criteria within  days prior to registration: stable and adequate cluster of differentiation  (CD) counts (>=  mm^), and serum HIV viral load of < , IU/ml; patients may be on or off anti-viral therapy so long as they meet the CD count criteria
Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYPA are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYPA are ineligible; patients with poorly controlled HIV are not eligible
Patients with active human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD) count is > /cu mm and their viral load is <  copies/ml; use of highly active antiretroviral treatment (HAART) is allowed
HIV positive patients on antiretroviral therapy regimen must be willing to suspend all highly active antiretroviral therapy (HAART) except in circumstances described
No known HIV-positive or AIDS unless patient is on a stable highly active antiretroviral therapy (HAART) regimen, have CD (cluster of differentiation ) counts >, with no detectable viral load on quantitative polymerase chain reaction test
Patients with active infections including known human immunodeficiency virus (HIV) are not eligible; HIV positive patients on highly active anti-retroviral therapy (HAART) with undetectable blood HIV levels are eligible; patients with a history or serological evidence of exposure to hepatitis B without active infection are eligible for this study
Human immunodeficiency virus positive (HIV+) patients will be considered eligible if they are on highly active anti-retroviral therapy (HAART) and have a cluster of differentiation (CD) count of >= /ul (HIV+ patients who are on HAART and have a CD count < /ul are eligible if the plasma viral load is below the level of detection according to the local assay)
HIV+ patients who are not on HAART or have a CD count of < /ul in the presence of detectable plasma viral load according to the local assay
In order for patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) to be eligible, they must be on a stable highly active antiretroviral therapy (HAART) regimen, have cluster of differentiation (CD) counts > , with no detectable viral load on quantitative polymerase chain reaction (PCR)
Patients with human immunodeficiency virus (HIV) are eligible if their CD count is >=  cells/mm^ and if they are not taking prohibited cytochrome (CYP)-interacting medications
HIV-positive patients on combination antiretroviral therapy which include cytochrome p inhibitors are ineligible; patients with CD counts less than  CD+ cells/mm^ and or a high viral load are ineligible
Human immunodeficiency virus (HIV)-positive patients are not excluded but, to enroll, must meet all of the below criteria:\r\n* HIV is sensitive to antiretroviral therapy\r\n* Must be willing to take effective antiretroviral therapy, if indicated\r\n* Cluster of differentiation (CD) count at screening >=  cells/mm^\r\n* No history of acquired immunodeficiency syndrome (AIDS)-defining conditions\r\n* If on antiretroviral therapy, must not be taking zidovudine or stavudine\r\n* Must be willing to take prophylaxis for pneumocystis jiroveci pneumonia (PCP) during therapy and until at least  months following the completion of therapy or until the CD cells recover to over  cells/mm^, whichever occurs later
Human immunodeficiency virus (HIV)-patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) \r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections \r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard PCR-based test
Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART)\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard PCR-based tests
For patients with unknown human immunodeficiency virus (HIV) status at the time of enrollment, HIV serology must be tested during screening; patients who are tested positive for HIV could be included if there is an adequate cluster of differentiation  (CD) count (> /ul) on a stable regimen of highly active anti-retroviral therapy (HAART) with no detectable or minimal viral burden, and no active infections
If HIV+ positive, all patients infected with human immunodeficiency virus (HIV) may be eligible for study provided that their CD+ count >= /uL; their viral load is undetectable; they are currently receiving highly active antiretroviral therapy (HAART)
Patient is human immunodeficiency virus (HIV) positive\r\nNote: patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective \r\n* They must have a cluster of differentiation (CD) count of greater than  cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection
Patients with a known confirmed diagnosis of human immunodeficiency virus (HIV) infection who are taking chronic anti-retroviral therapy (HAART) are ineligible if there is a potential for drug-drug interactions with the chemotherapeutic agents; patients with a known confirmed diagnosis of HIV infection who meet standard eligibility criteria and are not taking HAART with a potential for drug-drug interactions are eligible
Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease must: Have a CD count greater than or equal to  cells/uL within  days prior to beginning study therapy; Be off all antiretroviral therapy (prophylaxis/treatment) greater than  days prior to beginning study therapy; Have no evidence of opportunistic infections.
Patients with human immunodeficiency virus (HIV) infection are eligible provided they meet the following criteria: no evidence of co-infection with hepatitis B or C, cluster of differentiation (CD) count >=  cells/mm^, no resistant viral strains, on highly active antiretroviral treatment (HAART) therapy with a viral load <  RNA copies/ml, and no history of acquired immunodeficiency syndrome (AIDS)-defining conditions
Patients must not have human immunodeficiency virus (HIV) or be taking highly active antiretroviral therapy (HAART) therapy
Positive test for the human immunodeficiency virus (HIV), unless undetectable viral load within  months of enrollment (HIV ribonucleic acid [RNA] less than  copies/mL) on highly active antiretroviral therapy (HAART) therapy
Patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) are allowed on study if they have an undetectable viral load, cluster of differentiation (CD) >  and on stable highly active antiretroviral therapy (HAART) regimen for  month
Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\r\n* A stable regimen of highly active anti-retroviral therapy (HAART) using combination retroviral agents which are not CYPA inducers or inhibitors\r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests
Patients known to be positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have: \r\n* A stable regimen of highly active anti-retroviral therapy (HAART) \r\n* No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections \r\n* A CD count above  cells/mcL and an undetectable HIV viral load on standard PCR-based test\r\n* HIV testing is not required
Patients with human immunodeficiency virus (HIV) infection must be willing to comply with a regimen of highly active antiretroviral therapy (HAART)
Patients with human immunodeficiency virus (HIV) infection are not automatically excluded, but must meet the following criteria: cluster of differentiation  (CD) count is > /cu mm and their viral load is <  copies/ml; use of highly active antiretroviral therapy (HAART) is allowed
Human immunodeficiency virus (HIV)-positive diagnosis with a CD count of less than  mm or detectable viral load within past  months and receiving anti-retroviral therapy.
Human immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), cluster of differentiation (CD) counts are greater than  and viral load is undetectable
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible if they have been on antiretrovirals (ARVs) for >=  months and undetectable viral loads
Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective \r\n* They must have a CD count of greater than  cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible, unless the patients CD count is below the institutional lower limit of normal, or the patient is taking prohibited CYPA/ strong inhibitors or inducers
Patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) are allowed on study if they have an undetectable viral load, cluster of differentiation (CD) >  and are on a stable highly active antiretroviral therapy (HAART) regimen for  month prior to study enrollment
Human immunodeficiency virus (HIV) infection, unless the patient is receiving effective antiretroviral therapy with undetectable viral load and normal CD counts
Acute active (such as tuberculosis or malaria), serious, uncontrolled infection; participants with a CD count =< /mm^ (. x ^/L) will be excluded if they have had an opportunistic infection within the past  months, or if there is evidence of resistance to antiretroviral therapy (i.e., HIV viral load >=  copies/mL despite combination antiretroviral therapy for at least  months)
Treatment with highly active antiretroviral therapy (HAART) for at least  month
Human immunodeficiency virus (HIV) infection, unless receiving effective antiretroviral therapy with undetectable viral load and normal CD counts
Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:\r\n* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective \r\n* They must have a CD count of greater than  cells/mcL\r\n* They must not be receiving prophylactic therapy for an opportunistic infection\r\n* Must be on antiretroviral therapy and there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment\r\n* HIV viral load must be <  copies/ mm^ by standard clinical assays
Patients who are known to be human immunodeficiency virus (HIV)-positive will be excluded as highly active antiretroviral therapy (HAART) and HIV itself are known to cause peripheral neuropathy
Human immunodeficiency virus (HIV)+ positive patients are eligible if their CD+ count >= /uL and they have an undetectable viral load; in addition, they must be currently receiving highly active antiretroviral therapy (HAART) and be under the care of an infectious diseases specialist
Patients with a known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) will be eligible if:\r\n* They are generally healthy from an HIV perspective and on a stable anti-retroviral regimen for >  months\r\n* They have had no AIDS-defining conditions in the past  months other than historically low CD+ cell counts\r\n* They have an undetectable viral load on standard assays